Why Choose Us for Urologic Care?
Commitment to Minimally Invasive Techniques
Our surgeons have been innovators in developing and using minimally invasive surgical techniques. Some of the benefits of minimally invasive surgery include a faster recovery, less scarring and a shorter hospital stay when compared to traditional open procedures.
Often, our surgeons use the Da Vinci Surgical System, a sophisticated robotic device, to perform surgery for conditions such as prostate cancer. We're leaders in robotic urologic surgery, and have performed more robotic procedures than any other program in Illinois.
Quality of Life Issues
University of Chicago experts are sensitive to quality of life issues, particularly related to the patient's ability to urinate normally and to retain sexual functioning after cancer surgery.
Respect for Each Patient's Privacy
Many of the problems we treat are related to parts of the body and bodily functions that people are uncomfortable talking about. Too often, a person's embarrassment causes them to avoid or delay treatment. We understand. As a team, we reassure patients that there are solutions, yet remain sensitive to each patient's personal concerns and priorities.
Our section's diverse staff is recognized for their groundbreaking care and research. This staff includes board-certified urologists, urology fellows, molecular biologists, and nurse specialists.
Our urologists make full use of the expertise and resources available through the University of Chicago Medicine. They often collaborate with oncologists, radiologists, pathologists, nephrologists, gynecologists, and other specialists to meet patients' needs.
Behind the scenes, scientists here are exploring the molecular and genetic factors that contribute to cancers. These insights will help researchers detect cancer at an earlier stage, when it is more treatable, and may help to prevent secondary cancers in people who have had initial cancer treatment.
A large research team dedicated to fighting genitourinary cancers. The Genitourinary Oncology Research Program here includes 25 investigators and associate investigators, plus nine affiliated members.
Much of our research is translated into new treatment options. We offer these to patients through clinical trials and surgical innovations for conditions--such as cancer, impotence, and overactive bladder.
Our legacy for breakthrough treatments runs deep. In fact, University of Chicago urologist Charles Huggins, MD, was the first to recognize the role of hormones in treating advanced prostate cancer. His research laid the groundwork for hormonal treatment of prostate cancer and, later, for treatments of breast and gynecologic cancers. Dr. Huggins won the Nobel Prize for medicine in 1966.